Enable BRIUMVI Registry Research in Phoenix: What “Real-World” MS Data Is Designed to Learn

Adults in the Phoenix area who are looking for Enable BRIUMVI registry Phoenix often want a direct answer to one question: what real-world registry data can document without promising a personal treatment outcome. This guide explains how to use ANR’s public listing as a starting point while keeping medical decisions with your usual care team.

ANR’s Current Studies page says that Enable (TG1101-RMS406) is currently enrolling for this Phase 4 observational registry. It identifies the study as a longitudinal observational registry and lists TG Therapeutics as sponsor. Local status can change, so verify it directly with ANR before making plans.

What the Enable listing says

ANR lists Enable (TG1101-RMS406) as a Phase 4 observational registry involving adults with relapsing forms of multiple sclerosis who are prescribed BRIUMVI (ublituximab-xiiy). The listing says the registry follows safety, effectiveness, and patient experience in routine clinical practice over time. That is a research objective; it is not a statement that participation will improve a person’s MS or that the medication is right for everyone.

The key phrase is “real-world.” Registry research can collect structured information from people receiving care in usual clinical settings. It may help researchers understand patterns across a broader group, while an individual’s care still belongs with the clinician who knows that person’s history.

What a registry can—and cannot—answer

A registry is built to observe information consistently. Depending on the protocol, it may document treatment experience, health events, patient-reported information, and other outcomes across scheduled time points. The details matter, which is why the research team explains the specific consent and visit schedule.

What a registry cannot do is promise that a participant will have a particular response, fewer relapses, or a certain side-effect experience. It does not replace medical follow-up, and it should not be treated as a recommendation to begin, continue, or stop a medicine. If you have questions about BRIUMVI or another MS therapy, take them to the clinician managing your treatment.

A practical way to prepare

If you want to ask ANR about Enable, keep the conversation factual. Bring your current medication list, your relapsing MS diagnosis history as documented by your care team, and questions about visits, records, privacy, and communication with your treating clinician. Ask whether the listing’s current recruiting status applies to the Phoenix site when you contact ANR.

Do not assume eligibility based on a prescription alone. A study team reviews the protocol’s requirements, and participation is voluntary. You can decline or decide not to proceed after learning more.

Research information for adults in Arizona

Arizona Neuroscience Research (ANR) conducts neurology research for adults in Phoenix. Its public study page is designed to help prospective volunteers understand what is currently listed locally. It is not a medical record, a diagnosis tool, or a promise that a particular study is available to every person who has a related condition.

Research can offer an opportunity to learn about a protocol, but it is not a substitute for ongoing care. A research coordinator can explain screening, consent, required visits, and study procedures. Your own clinician remains the right person to advise you about symptoms, medicines, and treatment decisions.

What to bring to an initial research conversation

Before you contact a site, make a short, accurate list of current medicines, allergies, clinicians, major past treatments, and questions. Include practical details that can affect participation, such as work schedules, transportation, caregiver needs, and preferred contact methods. Do not feel pressure to have every record organized before you ask a first question; the site can explain what information is relevant if screening is available.

It is equally important not to self-screen. Meeting one item mentioned on a public page does not establish eligibility, and not recognizing a detail does not necessarily rule someone out. Research protocols include criteria that must be reviewed consistently by the site. Honest, complete information helps the team make a responsible determination.

Consent is a conversation, not a quick form

If a study team believes screening may be appropriate, consent materials should describe the purpose of the research, the study procedures, possible risks or discomforts, alternatives, privacy practices, compensation if any, and whom to contact with questions. Take time to read the materials. Ask for unfamiliar terms to be explained in plain language. You may also discuss the decision with family, a caregiver, or your usual healthcare professional.

Choosing not to participate is always an option. Joining a study is voluntary, and interest in a study does not obligate you to complete screening or enroll. A responsible decision is one made with current information, adequate time, and an understanding of how research will fit—or not fit—into your daily life.

When to seek urgent help

Research questions should never delay emergency care. Call 911 for symptoms such as sudden trouble speaking, new facial droop, sudden one-sided weakness or numbness, a seizure lasting five minutes or longer, severe trouble breathing or swallowing, fainting with injury, chest pain, or a sudden severe headache unlike your usual pattern. For non-emergency but concerning changes, contact your treating clinician or the appropriate care team promptly. If you are already in a study, follow the study’s safety-contact instructions as well.

Frequently asked questions

Is a registry the same as a trial that assigns a new treatment?

Not necessarily. ANR describes Enable as an observational registry. The research team can explain its specific protocol and what participation involves.

Does the registry determine whether BRIUMVI is right for me?

No. Medication suitability is an individual clinical question for your treating clinician.

Can I be guaranteed enrollment because I receive BRIUMVI?

No. The research site conducts screening and makes eligibility determinations under the protocol.

How do I check the local status?

Review ANR’s Current Studies page and use Volunteer Today to ask about current Phoenix enrollment.

What may happen after you request information

A first contact is usually an information step, not an enrollment decision. A member of the research team may explain the study at a high level, ask whether the condition named in the listing appears relevant, and describe how a formal screening conversation works. If the site is not currently screening, the team may explain whether there is a current way to receive accurate updates. Do not interpret an initial phone call, email, or form response as confirmation that you are in a study.

If screening is available, the process may include review of records, health questions, consent discussion, and protocol-required assessments. The order and exact details depend on the study. Some people learn during screening that the protocol is not a fit. That outcome is a normal part of responsible research and does not change the importance of continuing regular clinical care.

Practical questions about time, records, and expenses

Research participation can involve more than a visit on a calendar. Before deciding, ask how often visits may occur, what parts of the process are in person or remote if applicable, how long an appointment may take, and whether a support person may attend. Ask what records the site may request and whether you need to obtain anything from another office. You can also ask whether the consent materials describe any study-related costs, reimbursement, or compensation. Never assume that transportation, parking, missed work, or caregiving will be covered unless the study team provides that information in writing.

Be wary of any decision that feels rushed. A clear research conversation leaves room for practical planning. It also gives you an opportunity to compare the protocol’s demands with your usual medical appointments, work, family responsibilities, and energy level.

How research communication should fit with your care team

Research staff and treating clinicians have different roles. The research team follows the study protocol and monitors study-related procedures. Your treating clinicians manage your broader health needs and can advise you about individual medical decisions. Ask the site how important information is shared, whether you need to tell your clinician that you are considering a study, and whom to call if a health issue arises between visits.

Keep a current copy of your medication list and update both your care team and research team about changes as they occur. Do not assume that one office automatically knows what the other has been told. Clear communication is particularly important when a condition has symptoms that may change over time or when more than one specialist is involved.

Use online study information carefully

Study websites and registry records can be helpful educational tools, but they do not replace a local screening decision. A registry may describe a nationwide or global protocol, while ANR’s Current Studies page tells you what ANR currently lists locally. Review both with a practical goal: understand the study’s purpose and prepare questions. Avoid using a search result to decide that you must qualify, that a medication is appropriate, or that a local site is recruiting at a specific moment.

If you find conflicting details, ask ANR for the current local status and ask the research team which source they rely on for participants. Save the date you checked a webpage. Information can change as a study moves through setup, enrollment, follow-up, or completion.

A short question list to keep handy

  • What is the purpose of this study, in plain language?
  • Is the Phoenix site currently screening?
  • What would the first screening step involve?
  • How might study visits fit with my current care?
  • Who should I call about a new health concern?
  • What information should I discuss with my treating clinician?

Decisions beyond eligibility

Eligibility is only one part of deciding whether research is right for you. Even if a site determines that a person may participate, it is reasonable to ask whether the visit schedule, procedures, and communication approach fit their circumstances. A yes-or-no eligibility decision is not a judgment about anyone’s worthiness or about the seriousness of a condition. It is an application of a particular protocol at a particular time.

Consider how participation would fit alongside other responsibilities. A caregiver may have useful questions about transportation, note-taking, or what to do if symptoms change. Some adults may prefer to bring a support person to a consent discussion. Others may want time to compare the information with their usual care plan. These are normal parts of informed decision-making.

Keep a simple record of questions and updates

Before and after a conversation with a research site, write down the date, the study name, the contact method, and the main information you were given. This small record makes it easier to avoid confusing one study with another, especially when conditions or study names sound alike. It can also help you bring accurate questions to your next medical appointment.

Update your list when medicines, clinicians, or major health events change. Do not send sensitive medical details through an unapproved channel. Ask ANR which contact method it uses for research questions and records. Keeping a personal list is for communication and planning; it does not replace the medical record maintained by your care team.

Be cautious with health claims online

Search results, online communities, and promotional-looking posts can mix accurate facts with personal stories or outdated information. Focus on ANR’s current local listing, the official registry or sponsor source linked for a study, and the information provided during consent. Be particularly cautious about claims that a study guarantees access to treatment, cures a condition, accepts everyone with a diagnosis, or requires you to make an immediate medication change. Responsible research communication acknowledges uncertainty and gives people time to ask questions.

How to take the next step with ANR

For current local details, visit ANR Current Studies and use Volunteer Today to request information. ANR’s FAQs may also help you prepare. For the study’s broader public record, review the official study information. Asking for information does not guarantee a response, screening, or enrollment.

Educational disclaimer

This article is educational only and is not medical advice, a diagnosis, or a recommendation to start, stop, or change treatment. Study eligibility, medication suitability, and participation decisions are determined through the research site’s protocol and your own healthcare team. If you have urgent symptoms, seek emergency care rather than waiting for a research response.